Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis
M Inman, G Prater, H Fatima… - Clinical Kidney …, 2015 - academic.oup.com
Abstract C3 glomerulopathy (C3G) is characterized by C3 deposits with minimal
immunoglobulin deposition caused by alternative complement pathway dysregulation …
immunoglobulin deposition caused by alternative complement pathway dysregulation …
Eculizumab for treatment of rapidly progressive C3 glomerulopathy
M Le Quintrec, A Lionet, C Kandel, F Bourdon… - American Journal of …, 2015 - Elsevier
C3 glomerulopathy (C3G) is a prototypic complement-mediated kidney disease. Rapidly
progressive forms of C3G usually respond poorly to conventional treatments. We report on …
progressive forms of C3G usually respond poorly to conventional treatments. We report on …
Treating C3 glomerulopathy with eculizumab
T Welte, F Arnold, J Kappes, M Seidl, K Häffner… - BMC nephrology, 2018 - Springer
Abstract Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with
grim prognosis. The complex pathogenesis is just unfolding, and involves acquired as well …
grim prognosis. The complex pathogenesis is just unfolding, and involves acquired as well …
Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study
T Welte, F Arnold, L Westermann, FA Rottmann… - BMC nephrology, 2023 - Springer
Abstract Background C3 Glomerulopathy (C3G) is a rare glomerular disease caused by
dysregulation of the complement pathway. Based on its pathophysiology, treatment with the …
dysregulation of the complement pathway. Based on its pathophysiology, treatment with the …
Eculizumab and recurrent C3 glomerulonephritis
S Gurkan, B Fyfe, L Weiss, X Xiao, Y Zhang… - Pediatric Nephrology, 2013 - Springer
Background Hyperactivity of the alternative complement pathway is the principle defect in
C3 glomerulopathies (C3G). Eculizumab, a monoclonal antibody that binds C5 to prevent …
C3 glomerulopathies (C3G). Eculizumab, a monoclonal antibody that binds C5 to prevent …
Treatment of C3 glomerulopathy with complement blockers
M Vivarelli, F Emma - Seminars in thrombosis and hemostasis, 2014 - thieme-connect.com
C3 glomerulopathy (C3G) is a newly defined clinical entity comprising glomerular lesions
with predominant C3 staining. Under this definition are now included membranoproliferative …
with predominant C3 staining. Under this definition are now included membranoproliferative …
Pathology after eculizumab in dense deposit disease and C3 GN
LC Herlitz, AS Bomback, GS Markowitz… - Journal of the …, 2012 - journals.lww.com
Eculizumab might benefit C3 glomerulopathies mediated by dysregulation of the alternative
complement pathway. Here, we report renal biopsy findings before and after eculizumab …
complement pathway. Here, we report renal biopsy findings before and after eculizumab …
Timing of eculizumab therapy for C3 glomerulonephritis
L Rodriguez-Osorio, A Ortiz - Clinical kidney journal, 2015 - academic.oup.com
Eculizumab is an anti-C5 antibody that inhibits C5 cleavage and prevents the generation of
the terminal complement complex C5b-9. Eculizumab is licensed to treat paroxysmal …
the terminal complement complex C5b-9. Eculizumab is licensed to treat paroxysmal …
C3 glomerulopathy and eculizumab: a report on four paediatric cases
C Lebreton, J Bacchetta, F Dijoud, L Bessenay… - Pediatric …, 2017 - Springer
Background Eculizumab may be used to treat C3-glomerulopathy (C3G), a rare but severe
glomerular disease. Diagnosis and Treatment Patients 1, 2 and 3 were diagnosed with …
glomerular disease. Diagnosis and Treatment Patients 1, 2 and 3 were diagnosed with …
A case of C3 glomerulonephritis successfully treated with eculizumab
A Payette, N Patey, MA Dragon-Durey… - Pediatric …, 2015 - Springer
Abstract Background C3 glomerulonephritis (C3GN) is a rare form of glomerulopathy that is
characterized by predominant C3 deposits. Eculizumab, a humanized monoclonal C5 …
characterized by predominant C3 deposits. Eculizumab, a humanized monoclonal C5 …